PSEN1 and melanoma: To investigate whether PS-1 expression correlated with melanoma aggressiveness in vivo, we performed IHC on human melanoma tissue samples at different clinical stages and found that PS-1 expression was significantly lower in advanced-stage than in early-stage melanoma, demonstrating for the first time that PS-1 could be used as a marker of aggressive melanoma.